Primary Central Nervous System Lymphoma (PCNSL)

- Newly Diagnosed
  - IRB#11601 Phase II study of maintenance obinutuzumab for primary central nervous system lymphoma. Complete responders
  - IRB#1012 Phase I/II study involving Carboplatin and Methotrexate administered with Blood-Brain Barrier opening, and Rituximab

- Recurrent
  - No Trials Currently Available

CNS Embryonal or Germ Cell Tumor

- Newly Diagnosed
- Recurrent or Refractory

Glioma

- Newly Diagnosed or Recurrent
  - IRB#922 Phase II study involving Carboplatin, cyclophosphamide, and etoposide phosphate administered intra-arterially; randomized to receive/not receive Delayed Intravenous Sodium Thiosulfate Chemoprotection

- Recurrent
  - Anaplastic Oligodendroglioma or Oligoastrocytoma
  - IRB#2868 Phase I/II study involving Carboplatin, Melphalan and Etoposide Phosphate administered with Blood-Brain Barrier opening and Delayed Intravenous Otprotective Sodium Thiosulfate

High Grade Glioma

- IRB#5056 Phase I/II study involving Melphalan and Carboplatin administered with Blood-Brain Barrier opening and Delayed Intravenous Otoprotective Sodium Thiosulfate

IRB#1012 Phase I/II study involving Carboplatin and Methotrexate administered with Blood-Brain Barrier opening, and Rituximab

Chemoprotection

- IRB#5056 Phase I/II study involving Melphalan and Carboplatin administered with Blood-Brain Barrier opening and Delayed Intravenous Otoprotective Sodium Thiosulfate

http://www.ohsu.edu/research/rda/so/knight.php

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold